< Back | |
29 Oct 2015 | |
The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with reference to news reported on CNBC TV18 on October 29, 2015 - "Setback For Glenmark: 'Sanofi received license Vatelizumab in 2011 & Sanofi not to Pursue Development Of Vatelizumab Molecule'."<BR><BR>The reply is awaited. | |
View all announcements for GLENMARK PHARMACEUTICALS LTD. | Source: BSE India |